Supernus Pharmaceuticals, Inc. (SUPN) Stake Held by Fmr LLC

Fmr LLC continued to hold its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 104,100 shares of the specialty pharmaceutical company’s stock at the end of the 2nd quarter. Fmr LLC owned 0.21% of Supernus Pharmaceuticals worth $4,487,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in SUPN. Meeder Asset Management Inc. grew its stake in shares of Supernus Pharmaceuticals by 3,455.2% during the second quarter. Meeder Asset Management Inc. now owns 2,382 shares of the specialty pharmaceutical company’s stock valued at $103,000 after buying an additional 2,315 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Supernus Pharmaceuticals by 278.2% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,018 shares of the specialty pharmaceutical company’s stock valued at $130,000 after buying an additional 2,220 shares during the last quarter. Riverhead Capital Management LLC grew its stake in shares of Supernus Pharmaceuticals by 91.4% during the second quarter. Riverhead Capital Management LLC now owns 3,062 shares of the specialty pharmaceutical company’s stock valued at $132,000 after buying an additional 1,462 shares during the last quarter. Victory Capital Management Inc. grew its stake in shares of Supernus Pharmaceuticals by 17.7% during the second quarter. Victory Capital Management Inc. now owns 3,441 shares of the specialty pharmaceutical company’s stock valued at $148,000 after buying an additional 517 shares during the last quarter. Finally, OppenheimerFunds Inc. bought a new position in shares of Supernus Pharmaceuticals during the first quarter valued at about $205,000. Institutional investors and hedge funds own 95.06% of the company’s stock.

Shares of Supernus Pharmaceuticals, Inc. (NASDAQ SUPN) opened at $42.05 on Friday. The company has a quick ratio of 1.74, a current ratio of 1.94 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $2,131.89, a PE ratio of 36.89, a P/E/G ratio of 1.84 and a beta of 1.30. Supernus Pharmaceuticals, Inc. has a 12 month low of $17.25 and a 12 month high of $50.04.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its earnings results on Wednesday, August 2nd. The specialty pharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.24 by $0.08. The company had revenue of $75.83 million for the quarter, compared to analysts’ expectations of $68.54 million. Supernus Pharmaceuticals had a return on equity of 30.73% and a net margin of 41.10%. analysts predict that Supernus Pharmaceuticals, Inc. will post 1.04 EPS for the current fiscal year.

In other Supernus Pharmaceuticals news, insider Stefan K.F. Schwabe sold 95,000 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Thursday, September 7th. The stock was sold at an average price of $46.59, for a total transaction of $4,426,050.00. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Gregory S. Patrick sold 50,000 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Friday, September 8th. The shares were sold at an average price of $47.60, for a total value of $2,380,000.00. The disclosure for this sale can be found here. Insiders sold 153,709 shares of company stock worth $7,223,108 over the last three months. 6.70% of the stock is owned by insiders.

ILLEGAL ACTIVITY WARNING: This article was posted by Community Financial News and is owned by of Community Financial News. If you are reading this article on another site, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this article can be viewed at https://www.com-unik.info/2017/11/05/supernus-pharmaceuticals-inc-supn-stake-held-by-fmr-llc.html.

A number of research analysts have recently issued reports on SUPN shares. BidaskClub raised Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, August 17th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $49.00 price objective on shares of Supernus Pharmaceuticals in a research note on Tuesday, September 19th. Stifel Nicolaus reaffirmed a “buy” rating and set a $47.00 price objective (up from $36.00) on shares of Supernus Pharmaceuticals in a research note on Tuesday, July 18th. Jefferies Group LLC reaffirmed a “buy” rating and set a $51.00 price objective on shares of Supernus Pharmaceuticals in a research note on Friday, August 4th. Finally, Zacks Investment Research raised Supernus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $49.00 price objective on the stock in a research note on Thursday, July 13th. Four research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $49.78.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

What are top analysts saying about Supernus Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Supernus Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit